Indeed, the blockade of BCL2 activity has shown promising results in several cancers, such as pediatric lymphoblastic leukemia [43], neuroblastoma [44], melanoma [45], genitourinary neoplasm [30], and glioblastoma [46]. The gene discussed is BCL2; the disease is urogenital neoplasm.